

Kisunla™ (donanemab-azbt)

When requesting Kisunla™ (donanemab-azbt), the individual requiring treatment must be diagnosed with the FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-Approved Indication

Kisunla™ is indicated for the treatment of Alzheimer's disease. Treatment with Kisunla should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

Coverage Guidelines

Due to the lack of clinical efficacy data and safety concerns, approval is not recommended for Kisunla. The current Kisunla efficacy information is insufficient to determine if the medication demonstrates any clinically meaningful benefits; whereas, safety concerns have been demonstrated in clinical trials. In the absence of additional clinical trials, there is not enough information to support approval.

References

1. Kisunla™ (donanemab-azbt) [prescribing information]. Indianapolis, IN: Lilly; July 2025.
2. Alzheimer's Association. Alzheimer's disease facts and figures-2025. Available at: <https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf>. Accessed on July 9, 2025.
3. Sims JR, Zimmer JA, Evans CD, et al, for the TRAILBLAZER-ALZ 2 Investigators. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. *JAMA*. 2023;330(6):512-527.
4. Andrews JS, Desai U, Kirson NY, et al. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials. *Alzheimers Dement*. 2019;5:354-363.
5. Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer's disease. *N Engl J Med*. 2021;384(18):1691-1704.